Cucurbitacin E Alleviates Colonic Barrier Function Impairment and Inflammation Response and Improves Microbial Composition on Experimental Colitis Models
DOI: https://doi.org/10.2147/jir.s456353
IF: 4.5
2024-05-06
Journal of Inflammation Research
Abstract:Fengxia Zhan, 1 Wei Song, 2 Yong Fan, 3 Fangjian Wang, 1 Qian Wang 4, 5 1 Department of Clinical Laboratory, Hospital of Shandong University, Jinan, 250100, People's Republic of China; 2 Key Laboratory of Marine Eco-Environmental Science and Technology, First Institute of Oceanography, Ministry of Natural Resources, Qingdao, 266061, People's Republic of China; 3 Qingdao Mental Health Center, Qingdao University, Qingdao, People's Republic of China; 4 Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, 250012, People's Republic of China; 5 Department of Clinical Laboratory, Qilu Hospital (Qingdao), Shandong University, Qingdao, 266035, People's Republic of China Correspondence: Qian Wang, Email Purpose: Cucurbitacins, which are found in a variety of medicinal plants, vegetables and fruits, were known for their diverse pharmacological and biological activities, including anticancer, anti-oxidative and anti-inflammatory effects. Cucurbitacin E, one of the major cucurbitacins, was recently proved to inhibit inflammatory response. Methods: To explore the therapeutic effects of cucurbitacin E on colitis and the underlying mechanisms, male mice drunk water containing 2.5% dextran sulfate sodium (DSS) to establish colitis model and administrated with cucurbitacin E during and after DSS treatment. The disease activity index was scored and colonic histological damage was observed. Intestinal tight junction and inflammatory response were determined. 16S rRNA and transcriptome sequencing were performed to analyze gut microbiota composition and gene expression, respectively. Results: We found that cucurbitacin E alleviated DSS-induced body weight loss and impaired colonic morphology. Cucurbitacin E decreased the expression of inflammatory cytokines and cell apoptosis, and maintained barrier function. Additionally, cucurbitacin E retrieved DSS-induced alterations in the bacterial community composition. Furthermore, a variety of differentially expressed genes (DEGs) caused by cucurbitacin E were enriched in several pathways including the NFκB and TNF signaling pathways as well as in Th17 cell differentiation. There was a close relationship between DEGs and bacteria such as Escherichia-Shigella and Muribaculaceae. Conclusion: Our results revealed that cucurbitacin E may exert protective effects on colitis via modulating inflammatory response, microbiota composition and host gene expression. Our study supports the therapeutic potential of cucurbitacin E in colitis and indicates that gut microbes are potentially therapeutic targets. Keywords: barrier function, colitis, cucurbitacins, inflammation, microbiota Although factors such as damaged integrity, impaired immune ability, microbial disturbance, genetic susceptibility, and dietary modes have been shown to induce chronic inflammatory responses and cause inflammatory bowel diseases (IBD) including colitis, 1 its etiology remains to be fully elucidated. Nevertheless, the consensus is that the inhibition of intestinal inflammatory responses is effective in alleviating the symptoms of colitis. 2 Therefore, various dietary nutrients with strong anti-inflammatory effects can be used to prevent and treat IBD. Cucurbitacin, which are found in a variety of vegetables and fruits, including cucumber, squash, watermelon, and melon, are attracting increasing interest owing to their wide spectrum of pharmacological and biological activity. 3,4 Cucurbitacin E, an extract produced in abundance from Cucurbitaceae plants, exerts many beneficial effects, including anti-angiogenesis, 5 immunosuppressive 6,7 and antitumor 8 effects. Recently, its potential effects on the inflammatory response have been explored. Cucurbitacin E can inhibit inflammation via decreasing the cytochrome c oxidase subunit II expression and the production of TNF-α, IL-6, and IL-1β in RAW264.7 cells and bronchial epithelial cells treated with lipopolysaccharides. 9,10 Cucurbitacin E also decreases the TNF-α and INF-γ levels by inhibiting the NF-κB pathway in Jurkat T cells. 11 Although these results suggest that cucurbitacin E can directly affect inflammation in vitro, the underlying mechanisms remain to be elucidated. Recently, several studies have reported that the gut microbiota is critically involved in the development and treatment of colonic inflammation. However, the effects of cucurbitacin E on colitis and gut microbes have rarely been reported. Therefore, we conducted this study to explore the effects of cucurbitacin E on colitis caused by dextran sulfate sodium (DSS). Additionally, multi-omics analyses, -Abstract Truncated-
immunology